Cargando…
Advances in the Management of Recurrent Cervical Cancer: State of the Art and Future Perspectives
PURPOSE OF REVIEW: This review aims to give an insight into the currently available options for recurrent/metastatic (R/M) cervical cancer (CC), along with the main future, potentially practice-changing perspectives in this field. RECENT FINDINGS: Improvements in terms of tumor responses were observ...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10640496/ https://www.ncbi.nlm.nih.gov/pubmed/37870697 http://dx.doi.org/10.1007/s11912-023-01463-9 |
_version_ | 1785146644462829568 |
---|---|
author | Giudice, Elena Mirza, Mansoor Raza Lorusso, Domenica |
author_facet | Giudice, Elena Mirza, Mansoor Raza Lorusso, Domenica |
author_sort | Giudice, Elena |
collection | PubMed |
description | PURPOSE OF REVIEW: This review aims to give an insight into the currently available options for recurrent/metastatic (R/M) cervical cancer (CC), along with the main future, potentially practice-changing perspectives in this field. RECENT FINDINGS: Improvements in terms of tumor responses were observed with the use of immune checkpoints inhibitors (ICIs) in the previously treated CC population, followed by emerging striking data in terms of both antitumor activity and survival rates with the addition of the ICIs to platinum-based chemotherapy with or without bevacizumab in the first-line setting. Furthermore, the CC treatment landscape took another step forward in 2021 with the introduction of antibody–drug conjugates (ADCs) in the second-line setting, a highly targeted therapeutic strategy, which demonstrated to be a valid alternative option in the recurrent setting. SUMMARY: R/M CC is a hard-to-treat disease. However, after several years of limited systemic therapeutic options for the recurrent setting, the year 2018 marked a turning point for R/M CC patients, with the introduction of immunotherapy in the treatment paradigm, which completely reshaped the therapeutic armamentarium of the disease. Besides, another valuable treatment option represented by ADCs demonstrated its efficacy in the recurrent setting, thus further widening the treatment landscape for those patients. Yet, the introduction of immunotherapy in the upfront setting brought along new issues to be addressed such as the emerging ICIs resistance and the following need for alternative options in the post-ICIs setting. Several innovative therapeutic strategies are under investigation in ongoing clinical trials, with the aim of overcoming ICIs resistance with the addition of immunomodulatory agents or bypassing the ICIs resistance with novel alternative drugs. |
format | Online Article Text |
id | pubmed-10640496 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-106404962023-11-14 Advances in the Management of Recurrent Cervical Cancer: State of the Art and Future Perspectives Giudice, Elena Mirza, Mansoor Raza Lorusso, Domenica Curr Oncol Rep Article PURPOSE OF REVIEW: This review aims to give an insight into the currently available options for recurrent/metastatic (R/M) cervical cancer (CC), along with the main future, potentially practice-changing perspectives in this field. RECENT FINDINGS: Improvements in terms of tumor responses were observed with the use of immune checkpoints inhibitors (ICIs) in the previously treated CC population, followed by emerging striking data in terms of both antitumor activity and survival rates with the addition of the ICIs to platinum-based chemotherapy with or without bevacizumab in the first-line setting. Furthermore, the CC treatment landscape took another step forward in 2021 with the introduction of antibody–drug conjugates (ADCs) in the second-line setting, a highly targeted therapeutic strategy, which demonstrated to be a valid alternative option in the recurrent setting. SUMMARY: R/M CC is a hard-to-treat disease. However, after several years of limited systemic therapeutic options for the recurrent setting, the year 2018 marked a turning point for R/M CC patients, with the introduction of immunotherapy in the treatment paradigm, which completely reshaped the therapeutic armamentarium of the disease. Besides, another valuable treatment option represented by ADCs demonstrated its efficacy in the recurrent setting, thus further widening the treatment landscape for those patients. Yet, the introduction of immunotherapy in the upfront setting brought along new issues to be addressed such as the emerging ICIs resistance and the following need for alternative options in the post-ICIs setting. Several innovative therapeutic strategies are under investigation in ongoing clinical trials, with the aim of overcoming ICIs resistance with the addition of immunomodulatory agents or bypassing the ICIs resistance with novel alternative drugs. Springer US 2023-10-23 2023 /pmc/articles/PMC10640496/ /pubmed/37870697 http://dx.doi.org/10.1007/s11912-023-01463-9 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Giudice, Elena Mirza, Mansoor Raza Lorusso, Domenica Advances in the Management of Recurrent Cervical Cancer: State of the Art and Future Perspectives |
title | Advances in the Management of Recurrent Cervical Cancer: State of the Art and Future Perspectives |
title_full | Advances in the Management of Recurrent Cervical Cancer: State of the Art and Future Perspectives |
title_fullStr | Advances in the Management of Recurrent Cervical Cancer: State of the Art and Future Perspectives |
title_full_unstemmed | Advances in the Management of Recurrent Cervical Cancer: State of the Art and Future Perspectives |
title_short | Advances in the Management of Recurrent Cervical Cancer: State of the Art and Future Perspectives |
title_sort | advances in the management of recurrent cervical cancer: state of the art and future perspectives |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10640496/ https://www.ncbi.nlm.nih.gov/pubmed/37870697 http://dx.doi.org/10.1007/s11912-023-01463-9 |
work_keys_str_mv | AT giudiceelena advancesinthemanagementofrecurrentcervicalcancerstateoftheartandfutureperspectives AT mirzamansoorraza advancesinthemanagementofrecurrentcervicalcancerstateoftheartandfutureperspectives AT lorussodomenica advancesinthemanagementofrecurrentcervicalcancerstateoftheartandfutureperspectives |